- Home
- CELU vs PMI Comparison
CELU vs PMI Comparison
Compare CELU & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CELU | PMI |
|---|---|---|
| Founded | 2016 | 1981 |
| Country | United States | United States |
| Employees | 115 | 75 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 14.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CELU | PMI |
|---|---|---|
| Price | $0.73 | $0.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 168.4K | ★ 6.6M |
| Earning Date | 05-11-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.11 |
| 52 Week High | $4.35 | $13.68 |
Technical Indicators
Market Signals| Indicator | CELU | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 40.64 |
| Support Level | $0.69 | $0.15 |
| Resistance Level | $0.96 | $0.27 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 53.22 | 42.69 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.